European Investor
11 Apr 2026, 17:05
Johnson & Johnson presented new clinical data for its TECNIS PureSee intraocular lens (IOL) at the 2026 ASCRS Annual Meeting, highlighting strong visual performance and patient outcomes.
Results from multiple studies across the U.S., Europe, and Asia-Pacific showed the lens delivers excellent distance and intermediate vision, high contrast sensitivity, and low levels of visual disturbances, alongside high patient satisfaction and reduced dependence on glasses.
The findings reinforce the product’s positioning as a next-generation extended depth-of-focus lens, supporting Johnson & Johnson’s strategy to advance innovation in vision care and improve surgical outcomes for cataract patients.
Business Wire
Results from multiple studies across the U.S., Europe, and Asia-Pacific showed the lens delivers excellent distance and intermediate vision, high contrast sensitivity, and low levels of visual disturbances, alongside high patient satisfaction and reduced dependence on glasses.
The findings reinforce the product’s positioning as a next-generation extended depth-of-focus lens, supporting Johnson & Johnson’s strategy to advance innovation in vision care and improve surgical outcomes for cataract patients.
Business Wire